GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a health official said on Friday during a press briefing.

The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5 cases.

The Center for Biomedical Advanced Research and Development Authority (BARDA) is giving $72 million to three drugmakers to help fortify the US supply of bird flu vaccine ahead of 2025. The funding was disclosed by the Administration for Strategic Preparedness and Response,

Australia's CSL said on Wednesday it has got a contract from the U.S. Department of Health and Human Services (HHS) worth $121.4 million to increase the U.S. government's stockpile for bird flu vaccines to 40 million doses.

US has announced team up with multinational pharmaceutical companies CSL, GSK, Sanofi, and Seqirus for a $72 million worth of bird flu vaccine production initiative.On Friday, October 4, the US Federal health officials announced that they will

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines. | CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.

GSK, Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, Bloomberg News reported on Friday. The move comes as a multi-state outbreak among livestock and poultry has caused several human infections,

Sanofi (SNY), and CSL (CSLLY) win $72M U.S. contract to expand bird flu vaccine production amid fears of human transmission. Read more here.